Dianthus Therapeutics is on track to launch by midyear a late-stage clinical trial to confirm the safety and effectiveness of claseprubart (DNTH103), its experimental injection therapy, in people with generalized myasthenia gravis (gMG). The Phase 3 study, called EMERGE, will be registrational, meaning it will be designed to…
News
Switching from intravenous immunoglobulin (IVIG) to Vyvgart (efgartigimod alfa) was associated with fewer hospitalizations and better quality-of-life scores after the switch in people with generalized myasthenia gravis (gMG), according to a study in Japan. Also, a greater proportion of patients transitioning to Vyvgart achieved minimal manifestations, a…
The National Institute for Health and Care Excellence (NICE) has recommended that Rystiggo (rozanolixizumab-noli) be covered by England’s National Health Service (NHS) and provided at low or no cost to certain adults with hard-to-treat generalized myasthenia gravis (gMG). The recommendation makes Rystiggo the first gMG therapy to be…
A thymectomy, the surgical removal of the thymus gland, was projected to improve health outcomes and lower lifetime care costs when added to prednisolone-based care for eligible adults with myasthenia gravis (MG) in the U.K. Simulations in the study, which focused on eligible adults with generalized MG and…
The Tensilon test, though no longer used in the U.S., is generally safe and can accurately identify people with myasthenia gravis (MG) versus those without the autoimmune disease, according to a large study in Austria that assessed the effectiveness of the diagnostic tool. Also known as the edrophonium…
Nearly one in three people with generalized myasthenia gravis (gMG) experienced prolonged periods of few or no symptoms while on treatment with Imaavy (nipocalimab-aahu), according to more than two years of data from a global clinical trial. These and other data from the…
An investigational autoinjector device for administering Zilbrysq (zilucoplan), an approved therapy for generalized myasthenia gravis (gMG), is a safe and effective option for individuals now using the currently available prefilled syringe, according to new data from two clinical trials. Users were “highly satisfied” with the Zilbrysq autoinjector and…
Cemdisiran, an experimental therapy given by injection under the skin every three months, was shown to significantly and sustainably ease symptoms of generalized myasthenia gravis (gMG) in a global, late-stage clinical trial called NIMBLE. In addition to suggesting that cemdisiran is an effective gMG treatment, the trial results…
Kyverna Therapeutics’ experimental cell therapy KYV-101, now called mivocabtagene autoleucel (miv-cel), was associated with rapid, sustained symptom improvements in all seven participants with hard-to-treat generalized myasthenia gravis (gMG) in a clinical trial. The data specifically show that all seven treated to date with miv-cel in the Phase…
A new U.S.-based patient registry is enrolling people with myasthenia gravis (MG) to help researchers better understand how the disease progresses, how treatments are used in the real world, and how MG affects patients’ daily lives. Launched by Alira Health in partnership with the Autoimmune Neurology Alliance, the…
Recent Posts
- Accepting a challenge, because I want to be who I choose to be
- Late-stage trial of claseprubart will aim to confirm drug’s benefits for gMG
- Learning how to manage fear in life with myasthenia gravis
- Vyvgart may offer IVIG alternative for people with hard-to-control gMG
- Agency backs NHS coverage of Rystiggo for hard-to-treat gMG